Tafasitamab (original) (raw)
Тафаситамаб — лекарственный препарат, моноклональное антитело для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2020).
| Property | Value |
|---|---|
| dbo:abstract | Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. Tafasitamab was approved for medical use in the United States in July 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Tafasitamab represents an option for patients ineligible for CAR-T cell therapy. (en) Тафаситамаб — лекарственный препарат, моноклональное антитело для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2020). (ru) |
| dbo:alternativeName | Monjuvi, Minjuvi (en) |
| dbo:casNumber | 1422527-84-1 |
| dbo:drugbank | DB15044 |
| dbo:fdaUniiCode | QQA9MLH692 |
| dbo:kegg | D11601 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/tafasitamab |
| dbo:wikiPageID | 64703451 (xsd:integer) |
| dbo:wikiPageLength | 9011 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1090937425 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:International_nonproprietary_name dbr:Lenalidomide dbc:Orphan_drugs dbr:Food_and_Drug_Administration dbc:Monoclonal_antibodies dbr:Diffuse_large_B-cell_lymphoma dbr:CD19 dbr:Humanized_antibody dbr:First-in-class_medication dbr:Intravenous |
| dbp:atcPrefix | L01 (en) |
| dbp:atcSuffix | FX12 (en) |
| dbp:c | 6550 (xsd:integer) |
| dbp:casNumber | 1422527 (xsd:integer) |
| dbp:dailymedid | Tafasitamab (en) |
| dbp:drugbank | DB15044 (en) |
| dbp:h | 10092 (xsd:integer) |
| dbp:kegg | D11601 (en) |
| dbp:legalCa | Rx-only (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:mabType | mab (en) |
| dbp:n | 1724 (xsd:integer) |
| dbp:o | 2048 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Intravenous |
| dbp:s | 52 (xsd:integer) |
| dbp:source | zu/o (en) |
| dbp:synonyms | tafasitamab-cxix, MOR208, Xmab5574 (en) |
| dbp:target | dbr:CD19 |
| dbp:tradename | Monjuvi, Minjuvi (en) |
| dbp:type | mab (en) |
| dbp:unii | QQA9MLH692 (en) |
| dbp:wikiPageUsesTemplate | dbt:Antineoplastic-drug-stub dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:ClinicalTrialsGov dbt:Monoclonal-antibody-stub |
| dcterms:subject | dbc:Orphan_drugs dbc:Monoclonal_antibodies |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug |
| rdfs:comment | Тафаситамаб — лекарственный препарат, моноклональное антитело для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2020). (ru) Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. (en) |
| rdfs:label | Tafasitamab (en) Тафаситамаб (ru) |
| owl:sameAs | wikidata:Tafasitamab dbpedia-ru:Tafasitamab https://global.dbpedia.org/id/FbedJ |
| prov:wasDerivedFrom | wikipedia-en:Tafasitamab?oldid=1090937425&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Tafasitamab |
| is dbo:wikiPageRedirects of | dbr:Tafasitamab-cxix dbr:Monjuvi dbr:Minjuvi |
| is dbo:wikiPageWikiLink of | dbr:Gilles_Salles dbr:MorphoSys dbr:Tafasitamab-cxix dbr:ATC_code_L01 dbr:Monjuvi dbr:Diffuse_large_B-cell_lymphoma dbr:Incyte dbr:List_of_therapeutic_monoclonal_antibodies dbr:Minjuvi |
| is foaf:primaryTopic of | wikipedia-en:Tafasitamab |